Advertisement

Reactions Weekly

, Volume 1738, Issue 1, pp 129–129 | Cite as

Gefitinib/osimertinib

Development of resistance in lung adenocarcinoma: case report
Case report
  • 14 Downloads

Reference

  1. Zhang Y, et al. Newly emergent acquired egfr exon 18 g724s mutation after resistance of a t790m specific egfr inhibitor osimertinib in non-small-cell lung cancer: A case report. OncoTargets and Therapy 12: 51-56, 2019. Available from: URL: http://doi.org/10.2147/OTT.S188612 - China

Copyright information

© Springer Nature Switzerland AG 2019

Personalised recommendations